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Abstract—Drug development and personalized therapy require 
accurate and frequent monitoring of the metabolic response by 
living tissues to treatments. In case of high risk side effects, e.g. 
therapies with interfering anti-cancer molecule cocktails, direct 
monitoring of the patient’s drugs metabolism is essential as the 
metabolic pathways efficacy is highly variable on a patient-by-
patient basis. Currently, there are no fully mature point-of-care 
bio-sensing systems for drugs metabolism monitoring directly in 
blood. The aim of the paper is to investigate solutions to develop 
point-of-care systems for drugs monitoring in personalized 
therapy. P450 enzymes are the considered probe molecules as 
they are key proteins directly involved in drugs metabolism of 
humans. Sensitivity improvement is ensured by means of enzyme 
integration onto electrodes structured with carbon nanotubes. 
Component Off-The-Shelf (COTS) based circuits design is 
investigated toward bio-chip development. Results show that the 
proposed circuitry is suitable for the aim and confirm that 
nanotubes are detection enhancers.  
I.  INTRODUCTION  
Despite increased expenditure for drug development, 
sophisticated high-throughput techniques and apparently 
infinite possibilities offered by the rapidly expanding 
knowledge in genetics, still most effective drug therapies for 
major diseases provide benefit only to a fraction of patients 
[1]. This fraction is typically in the 20 to 50% range, while 
approximately 7% of hospitalized patients have serious 
adverse drug reactions [2]. This applies especially for main 
killers in Western countries, i.e. heart diseases and cancer. 
While ten years ago treatment of patients was thought to be 
based best on the mean results of randomized clinical trials 
and resulting guidelines (evidence based medicine), currently 
it is being increasingly recognized that any drug therapy needs 
to be selected and modified according to the individual patient 
(“individualization” or “personalization”). [3, 4].  
It has been known for decades that genetic polymorphism in 
P450 2D6 (a central enzyme in human metabolism) causes 
overdosing in “poor metabolizers” and under-dosing in 
“ultrafast metabolizers”. This is important e.g. in the treatment 
of chronic heart failure, hypertension (metoprolol), cancer 
(tamoxifen), pain, depression, or schizophrenia. However, the 
currently availability of tools for acquiring this knowledge is 
very limited and it is a major weakness of the concept of 
personalized medicine. Therefore, the development of Bio-
chip array platforms based on P450 proteins to detect the 
metabolism of pharmacological compounds is required to 
pursuit personalization in drug therapies.  
Nanostructures, such as metal nanoparticles and/or carbon 
nanotubes, may be used to improve the sensitivity of such 
P450-based biosensors.  It has been shown in 2005 that P450 
11A1 activity is highly enhanced when the cytochrome is 
immobilized onto screen-printed electrodes modified by gold 
nanoparticles [5]. 100 µM of cholesterol produced a current 
signal of a few µA when using riboflavin as molecular 
mediator between P450 11A1 and rhodium-graphite screen-
printed electrodes with an area of 20 mm2 [6]. On the other 
hand, a 10 µM concentration produced a current signal of 
more than 1 µA when using screen-printed electrodes of the 
same area but modified by gold nanoparticles [5]. More 
recently, further improvement in the sensitivity of cholesterol 
biosensor was demonstrated with nano-structuring by means 
of carbon nanotubes [7].  In this paper, the viability of nano-
structured electrodes functionalized with P450 enzymes has 
been investigated in order to evaluate the feasibility of an 
integrated bio-chip solution. Circuit architecture for 
electrochemical measurements has been designed, realized, 
and tested. 
II. CIRCUIT DEVELOPMENT 
A Printed Circuit Board (PCB) prototype has been realized 
using off-the-shelf components in order to investigate the 
feasibility of a fully integrable technology for electrochemical 
detection in drugs monitoring.  
  
A. Specifications 
Literature analysis of voltammetries with cytochrome P450 
as detection probe [8-13] provided the following specifications 
for the circuit which query a three electrodes configuration 
sensing spot: 
• At working electrode: must be able to generate a triangular 
wave fully customizable in amplitude range (-1000 ÷ 1000 
mV) and in scan rate (10 ÷ 100 mV/s). To realize a 
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Differential Pulse Voltammetry (DPV), thus to generate 
the sum of a triangular wave with a square one.  To apply a 
constant potential within the range from -1000 to 1000 
mV). To also allow Chronoamperometry (CA) 
experiments.  
• At reference electrode: to read the potential of the solution 
in the range -1000 ÷ 1000 mV. 
• At counter electrode: to read the current flowing through 
the solution (in the range -1000 ÷ 1000 A) due to the 
oxidation and reduction processes. 
 
B. Architecture 
The entire system consists of the electronic board for 
generation and acquisition of signals and by a remote PC. They 
communicate by using UART protocol to set the signals to be 
generated and to analyze signals detected on the sample. The 
board architecture is shown in Figure 1. The single components 
are R1 = 48 K, R2 = 47 K, R3 = 250 K, R4 = 100 K, R5 
in the range from 1 to 10 K R6 in the range from 2,5 to 250 
k. The two IC are U1 TLC2274AID (from Texas 
Instruments), U2 OP497GS (Analog Devices). Finally, the 
capacitors are C1 = 7,5 nF, C2 = 10 nF. This specific solution 
is able to scan a single site, but it was chosen to be realized as 
integrated circuit, and easily upgraded to a multiple read. 
The triangular wave is obtained by isolating the average 
value of a square wave with a duty cycle changing linearly in 
time. This result is obtained using a Bessel low-pass filter to 
keep only the DC value of the square wave. The solution gives 
a clean wave by using a single bit, and generates triangular 
signals with multiple frequencies with a low hardware effort. 
The microcontroller generates the square wave to be filtered 
and the square wave to be eventually summed for DPV. It also 
reads converts and sends the acquired signals to the remote PC 
for off-line analysis. The other logic on board has the purpose 
to shift and adapt the signals in the appropriate ranges.  
The entire architecture is easy to be realized in an 
integrated circuit. The low-pass Bessel filter is the only 
component requiring particular attention due to capacitors in 
the order of nF. Possible solutions of this problem are the use 
of switched capacitors or digital filters. 
III. MATERIALS AND METHODS 
A. Materials 
Carbon paste screen printed electrodes were purchased 
from Dropsens (model DRP-110). The electrodes were made 
of a graphite working electrode (area equal to 13 mm2), a 
graphite counter electrode and an Ag/AgCl reference 
electrode. The total area of the cell is 22 mm2. Cytochrome 
P450 2B4 was isolated and purified from the microsomal 
fraction of rabbit [14]. It was diluted in PBS buffer 50 mM at 
pH 7.4 with 20% glycerol content. Benzphetamine drug (from 
Sigma) was diluted in PBS pH 7.4 in aliquots of 50 nM, 5 M, 
500 M, 50 mM. Single wall carbon nanotubes (SWCNT, 
diameter 1-2 nm, length 30 µm, COOH content 2,73%) were 
purchased in powder (90% purity) from MKnano (Canada), 
diluted in chloroform to the concentration of 1 mg/mL [7].  
 
Fig. 1: Schematic of the PCB: a) Bessel Filter; b) Shifter & Range 
Adapters; c) Analogic Adder; d)I/V Converter. 
Samples were then sonicated for 20 minutes in order to 
form a homogeneous suspension. 
B. Preparation of enzyme electrode 
The working electrode was prepared in a two steps 
procedure [7]: 10 L of SWCNT solution were drop casted 
onto the working electrode and allowed to dry, then 3 L of 
P450 2B4 solution were spread onto the nanostructured 
working electrode and incubated at 4°C overnight. 
C. Electrochemical measurements 
The electrochemical response of P450 2B4 immobilized 
onto nano-structured electrodes was investigated by cyclic 
voltammetry under aerobic conditions. Voltammograms were 
acquired by using a Versastat 3 potentiostat (Princeton 
Applied Technologies). The electrodes were covered with 100 
L of PBS 100 mM at pH 7.4, or with the same volumes of 
PBS added to 1 L of Benzphetamine samples. The potential 
was swept in the range from -600 to +100 mV  vs Ag/AgCl 
using a scan rate of 100 mV/sec.  
IV. EXPERIMENTAL RESULTS 
A. PCB test for electrochemical detection 
The board has been tested with the standard cyclic 
voltammetry of Potassium Ferrocyanide. K4[Fe(CN)6)]·3H2O, 
at concentration of 30 mM, was diluted in PBS at 100mM and 
pH 7.4. Voltammograms reported in Figure 2 were acquired 
by using screen printed electrodes nano-structured with 
SWCNT and a scan rate of 100 mV/s.  
 
Fig. 2: Voltammogram acquired with the developed board in comparison with 
that from a lab station.  
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Curves shape unequivocally confirms a good performance of 
the architecture proposed in Figure 1 in comparison with that 
of an electrochemical lab station. Data compare quite well 
with those published in literature on the same redox reaction 
[15]. A low S/N ratio is also clearly evident. 
 
B. P450 2B4 response onto  SWCNT electrodes 
The peaks obtained in scans of SWCNT alone and 
SWCNT + P450 2B4 were analyzed. Figure 3 shows the first 4 
scans on PBS of an electrode nano-structured with SWCNT.  
The peak at -220 mV is due to the oxygen moieties derived 
from CNT [16, 17]. During the scans, we noticed an increase 
of the total voltammogram area and a decrease of the peak 
area. The capacitive baseline current was subtracted and 
Gaussian decomposition was used to define each contribution 
into peak shape. Figure 4 shows the peak acquired on 
cytochrome immobilized onto SWCNT. Peak shape is 
asymmetric and it is described using two different Gaussian 
curves. In case of SWCNT alone, data are well described by a 
single Gaussian curve. In case of both, the smaller peak has its 
center exactly positioned in the redox potential of P450 2B4 (-
350 mV) [14]. The Gaussian decomposition of SWCNT/P450 
2B4 peak strongly confirms similar features observed by using 
P450 11A1 and multi walled carbon nanotubes [7].  
 
 
 
 
Both SWCNT nano-structuring and P450 functionalization 
cause a huge increase in the total area of the voltammograms. 
(data not shown). Drop cast SWCNT behave like a 3D porous 
structure in which solution ions can penetrate [18]. It is also 
interesting to note that peak shifts towards more negative 
potentials after P450 2B4 functionalization, and the current 
has a severe decrease (Figure 5). This means that the 
electrolyte is less accessible to SWCNTs and more energy is 
required for electrons transfer. However, electrodes with 
Cytochrome and SWCNT present less energy for an improved 
electron transfer in comparison with electrodes functionalized 
with only P450 2B4. The use of CNT seems to confine peak 
positions into a narrowed potential window improving 
reproducibility. Multiple voltammetric scans force ions inside 
the SWCNT matrix and assist the electrical double layer 
formation around the SWCNT walls, as shown by the fist scan 
in Figure 3 which differs from others. The drop casting of 
proteins further alters charge balance because new charges are 
introduced onto the surface [19]. Capacitance increases till 
equilibrated double layer prevents further charged species to 
reach the surface. In our experiments we found that the total 
charge increases linearly with increasing volumes of SWCNT, 
but after the addiction of P450 this linearity is no more 
respected. 
 
 
 
 
Fig. 6: Ratio between P450 current sub-peak and CNT peak with 
respect to various benzphetamine addictions.  
 
Fig. 5: Peak current versus potential after Cytochrome P450, 
SWCNT, SWCNT and P450 drop casted. Values were obtained 
averaging the last three scans of three different electrodes. 
 
 
Fig. 4: Gaussian decomposition of acquired peak. with SWCNT and 
P450-2B4. Acquisitions were done by using a lab potentiostat. 
 
Fig. 3: Cyclic voltammograms of screen-printed graphite electrodes 
functionalized with SWCNT. Acquisitions were done by using a lab 
potentiostat. Scan 1 is different as due to ions charging. 
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Total capacitance saturation is reached in case of cytochromes 
and SWCNT (data not shown). This capacitive current limits 
the faradic current due to CNT oxygen and cytochrome. 
  
C. Benzphetamine Detection 
The voltammetric response to increasing concentrations of 
Benzphetamine (BZ) was also measured. Drops of 1 µL of BZ 
solution were progressively added to the 100 µL drop of PBS 
covering the electrode. Solutions with concentrations of 0.5 
nM, 50 nM, 5 uM, 500 uM of BZ were used. No peak current 
increase was clearly observed after BZ addiction, but the ratio 
of cytochrome sub-peak to the recorded voltammetric peak 
increase when more drug is added (Figure 6). This 
demonstrates the possibility to detect BZ. Moreover, the P450 
sub-peak shifted in presence of BZ accordingly with 
literature[14]. 
 
V. CONCLUSIONS 
 
In this paper, the feasibility of on-chip point-of-care devices 
for drugs monitoring in personalized therapies has been 
investigated. Data from electrochemical acquisition on carbon 
based screen printed electrodes have been shown. The 
electrodes were nano-structured by using Single Walled 
Carbon Nanotubes with diameter of 2 nm and presenting 
COOH functional groups. The nano-structured electrodes were 
functionalized by solution casting of P450 2B4 enzyme.  
The redox activity of the protein P450 2B4 onto these 
electrodes was demonstrated by using a lab electrochemical 
station. Detection of a common drug (Benzphetamine) was 
proved as well. Other pharmacological compounds, such as 
aminopyrine, 7-pentoxyresorufin, and lanosterol, are detectable 
by using the same P450 2B4 [14]. Moreover, different P450 
proteins may detect other drugs commonly used in 
pharmacological therapy [20]. The architecture of a detection 
circuit was designed, prototyped onto PCB, and successfully 
tested. Hence, the first step to realize point-of-care bio-chip to 
monitor drugs metabolism is overcome. Future works will 
focus on the fabrication and test of P450s based array for multi-
panel drugs detection and on VLSI fabrication and test of all 
the electronic circuitry required for the electrochemical 
detection as well as for multiplexing, storing and 
communication. 
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